For a patient with type 2 diabetes who cannot tolerate sodium‑glucose cotransporter‑2 inhibitors, glucagon‑like peptide‑1 receptor agonists, or metformin, refuses insulin, and has a hemoglobin A1c of 7.7%, what oral therapy should be prescribed?

Prescribe a Sulfonylurea or Thiazolidinedione (TZD)

For this patient with A1C 7.7% who cannot tolerate metformin, SGLT2 inhibitors, or GLP-1 receptor agonists and refuses insulin, I recommend starting a sulfonylurea (such as glyburide or glipizide) or a thiazolidinedione (pioglitazone) as the next-line oral therapy. Both classes can lower A1C by approximately 0.9-1.1% when used as monotherapy 1, 2.

Rationale for This Recommendation

The 2025 ADA Standards of Care 3 and 2022 AACE guidelines 4 establish that when metformin cannot be used and newer agents (SGLT2i, GLP-1 RA) are not tolerated, older oral agents remain appropriate options. While guidelines prioritize metformin first-line and SGLT2i/GLP-1 RA for cardiovascular benefits, your patient's intolerances eliminate these preferred options 5, 3.

The 2014 ADA algorithm 1 explicitly lists sulfonylureas and TZDs as acceptable second-line agents when metformin fails or cannot be used. Both classes have decades of clinical experience and proven A1C reduction efficacy 6, 1.

Choosing Between Sulfonylurea and TZD

Sulfonylurea advantages:

• Lower cost (generic availability) 1, 7
• Rapid glucose-lowering effect
• Simple once or twice daily dosing
• A1C reduction of approximately 1.0-1.5% 6, 1

Sulfonylurea disadvantages:

• High risk of hypoglycemia 1, 2, 8
• Weight gain (moderate, typically 2-4 kg) 1, 8
• May accelerate beta-cell failure over time 6

TZD (pioglitazone) advantages:

• Low hypoglycemia risk 1, 2
• Potential cardiovascular benefits in some studies 4
• Improves insulin sensitivity
• May benefit hepatic steatosis if present 4

TZD disadvantages:

• Fluid retention and edema 1, 2
• Contraindicated in NYHA Class III or IV heart failure 7
• Weight gain (can be substantial) 1, 8
• Increased fracture risk, especially in women 1
• Higher cost than sulfonylureas 1
• Slower onset of action (weeks to months for full effect)

My Specific Recommendation

Start with a sulfonylurea (glipizide 5 mg daily or glyburide 2.5 mg daily) if:

• The patient needs rapid glucose control
• Cost is a major concern
• No history of hypoglycemia or high hypoglycemia risk
• Patient can reliably eat regular meals

Start with pioglitazone 15-30 mg daily if:

• Patient has history of problematic hypoglycemia
• Patient has hepatic steatosis/NAFLD
• No heart failure (confirm no edema, dyspnea, or known cardiac dysfunction)
• Patient is male or postmenopausal female (lower fracture concern)
• Cost is not prohibitive

Critical Safety Monitoring

For sulfonylureas 1, 2:

• Educate extensively about hypoglycemia symptoms and treatment
• Advise taking with meals
• Consider lower starting doses in elderly or those with renal impairment
• Monitor for weight gain

For TZDs 1, 7:

• Screen for heart failure symptoms before starting (dyspnea, edema, orthopnea)
• Monitor weight and edema monthly initially
• Check liver function at baseline
• Counsel about fracture risk, especially in women
• Discontinue immediately if heart failure develops

Alternative Consideration: DPP-4 Inhibitors

If cost is not prohibitive, a DPP-4 inhibitor (sitagliptin, linagliptin) represents another option 1, 2, 3:

• Lower A1C reduction (~0.7%) compared to sulfonylureas/TZDs 2, 8
• Weight neutral 1, 2
• Low hypoglycemia risk 1, 2
• Generally well-tolerated
• More expensive than sulfonylureas/TZDs 1
• May require renal dose adjustment (except linagliptin) 7

However, given the A1C of 7.7% (0.7% above goal), the more robust glucose-lowering of sulfonylureas or TZDs makes them preferable to achieve target more reliably 1, 2.

Common Pitfalls to Avoid

1. Don't delay treatment intensification - therapeutic inertia worsens outcomes 2, 5, 3
2. Don't use TZDs in anyone with heart failure symptoms - this is an absolute contraindication 7
3. Don't underdose sulfonylureas - titrate to effective doses (glipizide up to 20 mg daily, glyburide up to 10 mg daily) if tolerated and needed 6
4. Don't forget lifestyle modification - continue emphasizing diet and exercise alongside pharmacotherapy 9, 1
5. Reassess insulin willingness - as disease progresses, insulin may become necessary; continue patient education about its eventual role 6, 2, 4